Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Study summary

This protocol serves as a mechanism to collect, store, and distribute bodily fluid and tissue samples obtained from Hematopoietic Cell Transplant (HCT) or novel immunotherapy patients and their donors at the Masonic Cancer Center in order to conduct correlative studies of the immune system, microbiota, and their interactions. Fluid (including but not limited to, blood, urine, saliva, cerebrospinal fluid, bronchoalveolar lavage fluid) sample log-in, processing, relabeling, and storage is performed by the Masonic Cancer Center (MCC) Translational Therapy Lab (TTL).

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedBlood Sample and Stool Sample

Plus 7 other study approaches.

Who it may be forRecurrent or relapsed

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Aug 21, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Masonic Cancer Center, University of Minnesota

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Masonic Cancer Center, University of Minnesota
Interventions being studied: Diagnostic Test: Blood Sample; Diagnostic Test: Stool Sample; Diagnostic Test: Urine Sample; Diagnostic Test: Bronchoalveolar Lavage (BAL) fluid; Diagnostic Test: Gastrointestinal biopsy x 2-4; Diagnostic Test: Skin biopsy; Diagnostic Test: Skin, mouth, and/or ocular swab; Diagnostic Test: Apheresis Product; Diagnostic Test: Final cellular product

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Recurrent or relapsed→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patients planning to undergo HCT or other cellular therapy/immunotherapy
Allogeneic related donors
Aged 0-80
Willing and able to sign voluntary written consent

Reasons someone may not be able to joinExclusion criteria

Patients whose medical record indicates that they have opted out of research

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Minnesota Masonic Cancer CenterMinneapolis, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 21, 2023. Always confirm current availability with the study team.

View original record ↗